Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; San Diego Veterans Affairs Healthcare System, San Diego, CA, USA.
Am J Emerg Med. 2022 Nov;61:235.e5-235.e6. doi: 10.1016/j.ajem.2022.08.012. Epub 2022 Aug 6.
The return of COVID-19 symptoms after Nirmatrelvir/Ritonavir (Nm/R) treatment is being increasingly reported. Limited evidence suggests most cases of rebound symptoms are mild and do not require further intervention. Here we present a male veteran reporting rebound symptoms who was found to be hypoxic with pulmonary emboli. Our case highlights the need to evaluate known complications of SARS-CoV-2 including venous thromboembolism in patients reporting recurring symptoms. Further, cases of severe rebound phenomenon should continue to be reported by clinicians to better appreciate the use of the Nm/R during the Omicron wave and among vaccinated persons.
在使用尼马曲韦/利托那韦（Nirmatrelvir/Ritonavir，简称 Nm/R）治疗后，新冠病毒症状再次出现的情况越来越多。有限的证据表明，大多数反弹症状较轻，无需进一步干预。在这里，我们报告了一例反弹症状的男性退伍军人，该患者被发现存在缺氧和肺栓塞。我们的病例强调了需要评估已知的新冠病毒并发症，包括在报告症状反复出现的患者中出现静脉血栓栓塞症。此外，临床医生应继续报告严重反弹现象的病例，以便更好地了解在奥密克戎浪潮期间和接种疫苗者中使用 Nm/R 的情况。
